Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts

By |2019-03-25T11:45:49-04:00March 25th, 2019|Categories: Bill Langbein, Case Study, Education, Healthcare, Insights, Pharmaceutical & Biotechnology|Tags: , , , , |

One of the strongest performing biopharmaceutical stocks this year is [...]